BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34150023)

  • 1. Sphingomyelin synthase 2 but not sphingomyelin synthase 1 is upregulated in ovarian cancer and involved in migration, growth and survival via different mechanisms.
    Jing F; Jing C; Dai X; Zhou G; Di S; Bi X; Dai T; Qin T; Hong L
    Am J Transl Res; 2021; 13(5):4412-4421. PubMed ID: 34150023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization.
    Li Z; Hailemariam TK; Zhou H; Li Y; Duckworth DC; Peake DA; Zhang Y; Kuo MS; Cao G; Jiang XC
    Biochim Biophys Acta; 2007 Sep; 1771(9):1186-94. PubMed ID: 17616479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deficiency of sphingomyelin synthase 1 but not sphingomyelin synthase 2 reduces bone formation due to impaired osteoblast differentiation.
    Matsumoto G; Hashizume C; Watanabe K; Taniguchi M; Okazaki T
    Mol Med; 2019 Dec; 25(1):56. PubMed ID: 31847800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.
    Lu H; Zhou L; Zuo H; Le W; Hu J; Zhang T; Li M; Yuan Y
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):217-228. PubMed ID: 33226447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcellular targeting domains of sphingomyelin synthase 1 and 2.
    Yeang C; Ding T; Chirico WJ; Jiang XC
    Nutr Metab (Lond); 2011 Dec; 8():89. PubMed ID: 22168400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All members in the sphingomyelin synthase gene family have ceramide phosphoethanolamine synthase activity.
    Ding T; Kabir I; Li Y; Lou C; Yazdanyar A; Xu J; Dong J; Zhou H; Park T; Boutjdir M; Li Z; Jiang XC
    J Lipid Res; 2015 Mar; 56(3):537-545. PubMed ID: 25605874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice.
    Dong J; Liu J; Lou B; Li Z; Ye X; Wu M; Jiang XC
    J Lipid Res; 2006 Jun; 47(6):1307-14. PubMed ID: 16508036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sphingomyelin synthase 2, but not sphingomyelin synthase 1, is involved in HIV-1 envelope-mediated membrane fusion.
    Hayashi Y; Nemoto-Sasaki Y; Tanikawa T; Oka S; Tsuchiya K; Zama K; Mitsutake S; Sugiura T; Yamashita A
    J Biol Chem; 2014 Oct; 289(44):30842-30856. PubMed ID: 25231990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of liver total sphingomyelin synthase deficiency on plasma lipid metabolism.
    Li Z; Chiang YP; He M; Zhang K; Zheng J; Wu W; Cai J; Chen Y; Chen G; Chen Y; Dong J; Worgall TS; Jiang XC
    Biochim Biophys Acta Mol Cell Biol Lipids; 2021 May; 1866(5):158898. PubMed ID: 33545384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a quantitative biochemical and cellular sphingomyelin synthase assay using mass spectrometry.
    Chen Y; Yurek DA; Yu L; Wang H; Ehsani ME; Qian YW; Konrad RJ; Jiang XC; Kuo MS; Cao G; Wang J
    Anal Biochem; 2013 Jul; 438(1):61-6. PubMed ID: 23535273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SMS overexpression and knockdown: impact on cellular sphingomyelin and diacylglycerol metabolism, and cell apoptosis.
    Ding T; Li Z; Hailemariam T; Mukherjee S; Maxfield FR; Wu MP; Jiang XC
    J Lipid Res; 2008 Feb; 49(2):376-85. PubMed ID: 17982138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Opposing Contribution of SMS1 and SMS2 to Glioma Progression and Their Value in the Therapeutic Response to 2OHOA.
    Fernández-García P; Rosselló CA; Rodríguez-Lorca R; Beteta-Göbel R; Fernández-Díaz J; Lladó V; Busquets X; Escribá PV
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30646599
    [No Abstract]   [Full Text] [Related]  

  • 13. Sphingomyelin synthase activity affects TRIF-dependent signaling of Toll-like receptor 4 in cells stimulated with lipopolysaccharide.
    Prymas K; Świątkowska A; Traczyk G; Ziemlińska E; Dziewulska A; Ciesielska A; Kwiatkowska K
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Feb; 1865(2):158549. PubMed ID: 31678513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Sphingomyelin synthase 2 (SMS2) in platelet activation and its clinical significance.
    Guo Y; Chang L; Zhang G; Gao Z; Lin H; Zhang Y; Hu L; Chen S; Fan B; Zhang S; Xue R
    Thromb J; 2021 Apr; 19(1):27. PubMed ID: 33910580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and characterization of selective human sphingomyelin synthase 2 inhibitors.
    Adachi R; Ogawa K; Matsumoto SI; Satou T; Tanaka Y; Sakamoto J; Nakahata T; Okamoto R; Kamaura M; Kawamoto T
    Eur J Med Chem; 2017 Aug; 136():283-293. PubMed ID: 28505533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sphingomyelin synthases and testicular function.
    Lee NP; Wong EW; Mruk DD; Cheng CY
    Expert Rev Endocrinol Metab; 2008 Sep; 3(5):593-601. PubMed ID: 30290412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency of sphingomyelin synthase-1 but not sphingomyelin synthase-2 causes hearing impairments in mice.
    Lu MH; Takemoto M; Watanabe K; Luo H; Nishimura M; Yano M; Tomimoto H; Okazaki T; Oike Y; Song WJ
    J Physiol; 2012 Aug; 590(16):4029-44. PubMed ID: 22641779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor.
    Li Y; Huang T; Lou B; Ye D; Qi X; Li X; Hu S; Ding T; Chen Y; Cao Y; Mo M; Dong J; Wei M; Chu Y; Li H; Jiang XC; Cheng N; Zhou L
    Eur J Med Chem; 2019 Feb; 163():864-882. PubMed ID: 30580239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.
    Bilal F; Montfort A; Gilhodes J; Garcia V; Riond J; Carpentier S; Filleron T; Colacios C; Levade T; Daher A; Meyer N; Andrieu-Abadie N; Ségui B
    Front Pharmacol; 2019; 10():443. PubMed ID: 31114500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sphingomyelin Synthase 2 Inhibition Ameliorates Cerebral Ischemic Reperfusion Injury Through Reducing the Recruitment of Toll-Like Receptor 4 to Lipid Rafts.
    Xue J; Yu Y; Zhang X; Zhang C; Zhao Y; Liu B; Zhang L; Wang L; Chen R; Gao X; Jiao P; Song G; Jiang XC; Qin S
    J Am Heart Assoc; 2019 Nov; 8(22):e012885. PubMed ID: 31718447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.